Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536094 · ClinicalTrials.gov registry record · Phase 3
School-based Treatment for Anxious Children
A Phase 3 study of Anxiety Disorders, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00536094 is a Phase 3 study of Anxiety Disorders that has completed, run by Johns Hopkins University. The registered enrollment target is 40 participants, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00536094, a Phase 3 study of Anxiety Disorders, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effectiveness of a school-based cognitive behavior therapy in urban, predominantly low-income, African-American children diagnosed with an anxiety disorder.
Conditions Studied
Interventions
- BEHAVIORAL Treatment as usual (TAU)
- BEHAVIORAL Cognitive behavioral therapy (CBT)
Study Locations (1)
Maryland
- Johns Hopkins School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536094
The ClinicalTrials.gov registry entry for NCT00536094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (96% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which Treatment as usual (TAU) is the first listed.
NCT00536094 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00536094 about?
NCT00536094 is a clinical study titled "School-based Treatment for Anxious Children". This study will determine the effectiveness of a school-based cognitive behavior therapy in urban, predominantly low-income, African-American children diagnosed with an anxiety disorder.
What is the current status of trial NCT00536094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2009-12.
What conditions does trial NCT00536094 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT00536094?
The interventions under investigation include: Treatment as usual (TAU) (BEHAVIORAL), Cognitive behavioral therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00536094?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00536094 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
RECRUITING · Phase 3
-
Fluoxetine vs CBT in Childhood Anxiety Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
COMPLETED · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.